Diabetes Care, Vol 17, Issue 1 6-12, Copyright © 1994 by American Diabetes Association

ARTICLES

Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity

G Ruotolo, M Parlavecchia, MR Taskinen, G Galimberti, A Zoppo, NA Le, F Ragogna, P Micossi and G Pozza
Department of Medicine (Laboratory of Lipoprotein Metabolism and Atherosclerosis), Scientific Institute H San Raffaele, University of Milan, Italy.

OBJECTIVE--To characterize the effects of intraperitoneal insulin pump therapy on lipoprotein composition and lipolytic enzyme activity in patients with insulin-dependent diabetes mellitus (IDDM). RESEARCH DESIGN AND METHODS--Ten IDDM patients were studied 3 times: when receiving conventional subcutaneous insulin therapy and at 3 and 9 months from the initiation of intraperitoneal insulin regimen. Ten nondiabetic subjects matched for age, sex, and body weight were studied as controls. Levels of cholesterol, triglycerides, apolipoprotein A-I (apoA-I) and B (apoB) were measured in total plasma and lipoprotein fractions (very-low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], low-density lipoprotein [LDL], and high-density lipoprotein [HDL]: HDL2 and HDL3). Postheparin plasma lipoprotein lipase and hepatic lipase activities were determined by an immunochemical method. RESULTS--IDDM patients showed higher levels of HDL3 and lower levels of HDL2 particles during intraperitoneal insulin therapy in comparison with subcutaneous insulin therapy. Both cholesterol and apoA-I significantly increased in HDL3 and decreased in HDL2 during intraperitoneal treatment. Plasma total cholesterol significantly decreased in the diabetic patients at 3 months of intraperitoneal insulin therapy compared with both subcutaneous insulin regimen and control subjects. IDL triglyceride concentrations during intraperitoneal treatment were significantly lower than those seen with subcutaneous therapy. Furthermore, triglyceride:apoB ratio in VLDL and cholesterol:apoB ratio in LDL significantly decreased in IDDM patients treated by intraperitoneal insulin. A significant increase in the activity of hepatic lipase with intraperitoneal insulin therapy by 9 months compared with subcutaneous insulin therapy has been shown. CONCLUSIONS--The increased activity of hepatic lipase after intraperitoneal insulin administration in IDDM patients appears to be one of the main determinants of lipoprotein changes observed, resulting in the normalization of lipoprotein composition during this mode of therapy. The normal inverse relationship between VLDL triglycerides and HDL cholesterol, which was not present in IDDM patients with subcutaneous therapy, was restored with intraperitoneal insulin regimen.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C.-C. Szeto, K.-M. Chow, C.-B. Leung, B. C.-H. Kwan, K.-Y. Chung, M.-C. Law, and P. K.-T. Li Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1697 - 1702. [Abstract] [Full Text] [PDF]

				L. Duvillard, E. Florentin, S. Baillot-Rudoni, M.-L. Lalanne-Mistrich, A. Brun-Pacaud, J.-M. Petit, J.-M. Brun, P. Gambert, and B. Verges Comparison of Apolipoprotein B100 Metabolism between Continuous Subcutaneous and Intraperitoneal Insulin Therapy in Type 1 Diabetes J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5761 - 5764. [Abstract] [Full Text] [PDF]

				J. G. Schneider, M. von Eynatten, S. Schiekofer, P. P. Nawroth, and K. A. Dugi Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo Diabetes Care, September 1, 2005; 28(9): 2181 - 2186. [Abstract] [Full Text] [PDF]

				B. Perret, L. Mabile, L. Martinez, F. Terce, R. Barbaras, and X. Collet Hepatic lipase: structure/function relationship, synthesis, and regulation J. Lipid Res., August 1, 2002; 43(8): 1163 - 1169. [Abstract] [Full Text] [PDF]

				I. J. Goldberg Diabetic Dyslipidemia: Causes and Consequences J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 965 - 971. [Full Text]